Therapeutic agents targeting GPR35

A compound having the structure of Formula (I):

• wherein:
• R1 is —C1-6alkyl-C(O)N(R10)2, —C1-6alkyl-C(O)N(H)(OH), —C1-6alkyl-C(O)N(H)(OCH3), —C1-6alkyl-C(O)N(H)S(O)2N(R10)2, —O—C1-6alkyl-C(O)N(R10)2, —O—C1-6alkyl-C(O)N(H)(OH), —O—C1-6alkyl-C(O)N(H)(OCH3), —O—C1-6alkyl-C(O)N(H)S(O)2N(R10)2, —C(H)═R5, —C1-6alkyl-R5, or —C1-6alkyl-C2-9heteroaryl, wherein —C1-6alkyl-C2-9heteroaryl is optionally substituted on the heteroaryl with one, two, or three groups independently selected from halogen, C1-6alkyl, C1-6haloalkyl, and —C(O)OR10;
• R2 is H, —OH, —N(R10)2, —O—C1-6alkyl, —C1-6alkyl-OH, —C1-6alkyl-OR9, —C1-6alkyl-N(R10)2, C1-6haloalkyl;
• each R3 is independently selected from halogen, —CN, —OH, —OR9, —SR9, —N(R10)2, —NO2, —S(O)R9, —S(O)2R9, —NHS(O)2R9, —S(O)2N(R10)2, —C(O)R9, —C(O)OR10, —OC(O)R9, —C(O)N(R10)2, —OC(O)N(R10)2, —NR10C(O)N(R10)2, —NR10C(O)R9, —NR10C(O)OR9, C1-6alkyl, —C1-6alkyl-OH, —C1-6alkyl-OR9, —C1-6alkyl-N(R10)2, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-8cycloalkyl, and —C1-6alkyl-C3-8cycloalkyl;
• each R4 is independently selected from halogen, —CN, —OH, —OR9, —SR9, —N(R10)2, —S(O)R9, —S(O)2R9, —NHS(O)2R9, —S(O)2N(R10)2, —C(O)NHS(O)2N(R10)2, —C(O)R9, —C(O)OR10, —OC(O)R9, —C(O)N(R10)2, —OC(O)N(R10)2, —NR10C(O)N(R10)2, —NR10C(O)R9, —NR10C(O)OR9, C1-6alkyl, —C1-6alkyl-R9, —C1-6alkyl-OH, —C1-6alkyl-OR9, —C1-6alkyl-N(R10)2, —C1-6alkyl-C(O)OR10, C2-6alkenyl, —C2-6alkenyl-C(O)OR10, C2-6alkynyl, C1-6haloalkyl, C1-6haloalkyl-OH, C3-8cycloalkyl, —C1-6alkyl-C3-8cycloalkyl, phenyl, —C1-6alkyl-phenyl, C2-9heterocycloalkyl, —C1-6alkyl-C2-9heterocycloalkyl, and C1-9heteroaryl;
• wherein C3-8cycloalkyl, —C1-6alkyl-C3-8cycloalkyl, phenyl, —C1-6alkyl-phenyl, and C1-9heteroaryl are optionally substituted on the ring structure with one, two, or three groups independently selected from halogen, —C(O)OR10, C1-6alkyl, C1-6haloalkyl, C3-8cycloalkyl, and C2-9heterocycloalkyl;
• and wherein C2-9heterocycloalkyl and —C1-6alkyl-C2-9heterocycloalkyl are optionally substituted on the ring structure with one, two, or three groups independently selected from halogen, —C(O)OR10, C1-6alkyl, C1-6haloalkyl, and oxo;
• R5 is C2-9heterocycloalkyl optionally substituted on the heterocycloalkyl with one, two, or three groups independently selected from halogen, C1-6alkyl, C1-6haloalkyl, —C(O)OR10, and oxo;
• each R9 is independently selected from C1-6alkyl, C1-6haloalkyl, C3-8cycloalkyl, —C1-6alkyl-C3-8cycloalkyl, phenyl, —C1-6alkyl-phenyl, C2-9heterocycloalkyl, —C1-6alkyl-C2-9heterocycloalkyl, C2-9heteroaryl, and —C1-6alkyl-C2-9heteroaryl, wherein C1-6alkyl, phenyl, —C1-6alkyl-phenyl, —C1-6alkyl-C2-9heterocycloalkyl, C2-9heteroaryl, and —C1-6alkyl-C2-9heteroaryl are optionally substituted on the ring structure with one or two groups independently selected from C1-6alkyl, —OR11, —N(R11)2, C1-6alkyl, C3-8cycloalkyl, —N(R11)C(O)R12, —C(O)R12, and —C(O)OR12;
• each R10 is independently selected from H, C1-6alkyl, C1-6haloalkyl, C3-8cycloalkyl, —C1-6alkyl-C3-8cycloalkyl, phenyl, —C1-6alkyl-phenyl, and C2-9heteroaryl, wherein C1-6alkyl, phenyl, —C1-6alkyl-phenyl, and C2-9heteroaryl are optionally substituted on the ring stucture with one or two groups independently selected from halogen, C1-6alkyl, —N(R11)2, and —C(O)OR12;
• or two R10 and the nitrogen atom to which they are attached are combined to form a 5- or 6-membered heterocycloalkyl ring optionally substituted with one, two, or three groups independently selected from C1-6alkyl, oxo, and —C(O)OH;
• each R11 is independently selected from H and C1-6alkyl;
• each R12 is independently selected from H and C1-6alkyl;
• n is 0, 1, 2, or 3;
• and
• p is 0, 1, 2, 3, or 4;
• or a pharmaceutically acceptable salt or solvate thereof.